Evidence map›Paper›PMID 36569222›Full record

ArticleDisease markers2022

A Novel Inflammatory and Nutritional Prognostic Scoring System for Nonpathological Complete Response Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy.

Cong Jiang, Yuting Xiu, Shiyuan Zhang, Xiao Yu, Kun Qiao, Yuanxi Huang

Abstract read
In one paragraph

Article in Disease markers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Cong Jiang *Department of Breast Surgery, Harbin Medical University Cancer Hospital, Harbin, China.ORCID https://orcid.org/0000-0002-6436-4386
Yuting Xiu *Department of Breast Surgery, Harbin Medical University Cancer Hospital, Harbin, China.
Shiyuan ZhangDepartment of Breast Surgery, Harbin Medical University Cancer Hospital, Harbin, China.
Xiao YuDepartment of Breast Surgery, Harbin Medical University Cancer Hospital, Harbin, China.
Kun QiaoDepartment of Breast Surgery, Harbin Medical University Cancer Hospital, Harbin, China.ORCID https://orcid.org/0000-0002-1830-4702
Yuanxi HuangDepartment of Breast Surgery, Harbin Medical University Cancer Hospital, Harbin, China.ORCID https://orcid.org/0000-0002-6265-0688

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: It has been demonstrated that inflammatory and nutritional variables are associated with poor breast cancer survival. However, some studies do not include these variables due to missing data. To investigate the predictive potential of the INPS, we constructed a novel inflammatory-nutritional prognostic scoring (INPS) system with machine learning. Methods: This retrospective analysis included 249 patients with malignant breast tumors undergoing neoadjuvant chemotherapy (NAC). After comparing seven potent machine learning models, the best model, Xgboost, was applied to construct an INPS system. K-M survival curves and the log-rank test were employed to determine OS and DFS. Univariate and multivariate analyses were carried out with the Cox regression model. Additionally, we compared the predictive power of INPS, inflammatory, and standard nutritional variables using the Results: After comparing seven machine learning models, it was determined that the XGBoost model had the best OS and DFS performance (AUC = 0.865 and 0.771, respectively). For overall survival (OS, cutoff value = 0.3917) and disease-free survival (cutoff value = 0.4896), all patients were divided into two groups by the INPS. Those with low INPS had higher 5-year OS and DFS rates (77.2% vs. 50.0%, Conclusion: The INPS was an independent predictor of OS and DFS and exhibited better predictive ability than BMI, PNI, and MLR. For patients undergoing NAC for nonpCR breast cancer, INPS was a crucial and comprehensive biomarker. It could also forecast individual survival in breast cancer patients with low HER-2 expression.

Indexed as

Breast NeoplasmsFemaleHumansKaplan-Meier EstimateNeoadjuvant TherapyPrognosisRetrospective Studies

Identifiers

PMID36569222
PMCPMC9788886

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.